Cancer drug shortages lead to higher costs, greater risk

Drug Shortages Delay Cancer Clinical Trials.

T he mean survival time for people older than 60 years with acute myeloid leukemia (AmL) is about 7 months. only 15% survive 5 years or longer, and that percentage hasn't changed in decades. the poor prognosis for these patients is due in part to the fact that many cannot tolerate the toxic chemotherapy used as first-line treatment, a combination of cytarabine and daunorubicin. Both are generic...

FDA's role in responding to drug shortages.

The Drug Shortage Program at the Food and Drug Administration (FDA) is a division of the Center for Drug Evaluation and Research (CDER), one of the five centers within FDA. The four other centers include the Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, Center for Food Safety and Applied Nutrition, and Center for Veterinary Medicine. At the Drug Short...

Drug shortages: causes and cautions.

Drug shortages have increasingly been a problem for pharmacists and clinicians over the past decade. Clinicians need to be aware of the various causes of drug shortages and the issues that may arise as a result, particularly as they relate to medication safety. Numerous resources and strategies are available to mitigate the effects of drug shortages, and clinicians should work with their health...

Higher Deficit Policies Lead to Higher Inflation

Oncology Drug Shortages in America

J Adv Pract Oncol 2012;3:96–102 T he issue of drug shortages is only one of the many crucial concerns facing oncology advanced practitioners (APs) in the United States today. However, it may be the most critical issue affecting shortand long-term patient outcomes. Shortterm outcomes may be affected by treatment delays, treatment with less effective alternatives, and increased toxicity. Long-ter...